Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.
BACKGROUND: Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with th...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1826283830049243136 |
|---|---|
| author | Maclaren, R Groppe, M Barnard, A Cottriall, C Tolmachova, T Seymour, L Clark, K During, M Cremers, F Black, G Lotery, A Downes, S Webster, A Seabra, M |
| author_facet | Maclaren, R Groppe, M Barnard, A Cottriall, C Tolmachova, T Seymour, L Clark, K During, M Cremers, F Black, G Lotery, A Downes, S Webster, A Seabra, M |
| author_sort | Maclaren, R |
| collection | OXFORD |
| description | BACKGROUND: Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease. METHODS: In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213. FINDINGS: Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector. INTERPRETATION: The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning. FUNDING: UK Department of Health and Wellcome Trust. |
| first_indexed | 2024-03-07T01:04:44Z |
| format | Journal article |
| id | oxford-uuid:8af257ea-9813-41f4-9e35-1c982cb32c7c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:04:44Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:8af257ea-9813-41f4-9e35-1c982cb32c7c2022-03-26T22:34:53ZRetinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8af257ea-9813-41f4-9e35-1c982cb32c7cEnglishSymplectic Elements at Oxford2014Maclaren, RGroppe, MBarnard, ACottriall, CTolmachova, TSeymour, LClark, KDuring, MCremers, FBlack, GLotery, ADownes, SWebster, ASeabra, MBACKGROUND: Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease. METHODS: In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213. FINDINGS: Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector. INTERPRETATION: The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning. FUNDING: UK Department of Health and Wellcome Trust. |
| spellingShingle | Maclaren, R Groppe, M Barnard, A Cottriall, C Tolmachova, T Seymour, L Clark, K During, M Cremers, F Black, G Lotery, A Downes, S Webster, A Seabra, M Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title | Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title_full | Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title_fullStr | Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title_full_unstemmed | Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title_short | Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. |
| title_sort | retinal gene therapy in patients with choroideremia initial findings from a phase 1 2 clinical trial |
| work_keys_str_mv | AT maclarenr retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT groppem retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT barnarda retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT cottriallc retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT tolmachovat retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT seymourl retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT clarkk retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT duringm retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT cremersf retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT blackg retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT loterya retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT downess retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT webstera retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial AT seabram retinalgenetherapyinpatientswithchoroideremiainitialfindingsfromaphase12clinicaltrial |